Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of MALT Lymphoma
Investigate the efficacy and safety of Orelabrutinib followed by response-adapted ultra-low dose 4Gy radiation in the treatment of local-stage MALT lymphoma
Lymphoma, B-Cell, Marginal Zone
DRUG: Orelabrutinib|RADIATION: response-adapted radiation
1-year event-free survival (EFS), the period from the date of patients sign informed consent to the observed event for any reason, 1 year
6-months CR rate, the ratio of numbers of patients with complete response to all the participants receiving treatment, up to 6 months|2-year event-free survival (EFS), the period from the date of patients sign informed consent to the observed event for any reason, From date of patients sign informed consent until the date of first documented event, progression or date of death from any cause, whichever came first, assessed up to 2 years|2-year progression-free survival (PFS), the period from the date of patients sign informed consent to the observed progression of the disease or the occurrence of death for any reason, From date of patients sign informed consent until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years|2-year overall survival rate, time between the date of patients sign informed consent and the date of death or the date of last follow-up time, From date of patients sign informed consent until the date of death or the date of last follow-up time, whichever came first, assessed up to 2 years|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0, Record the name of adverse events and number of participants with treatment-related adverse events as assessed by CTCAE v5.0, Throughout the treatment period, up to 1 year|Quality of life questionnaire(EORTC QLQ-C30), evaluate patients' quality of life by questionnaire using EORTC QLQ-C30.There are a total of 30 entries. Among them, items 29 and 30 are divided into seven levels, ranging from 1 to 7 points based on their answer options; The other items are divided into four levels: none, a little, many to many, and are rated directly on a scale of 1 to 4., Up to 1 year
This prospective, multicenter trial is trying to evaluate the efficacy and safety of Orelabrutinib followed by response-adapted ultra-low dose 4Gy radiation as first-line treatment of local-stage mucosa associated lymphoid tissue extranodal marginal zone lymphoma